KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Current Assets (2016 - 2025)

Sarepta Therapeutics has reported Current Assets over the past 16 years, most recently at $2.5 billion for Q4 2025.

  • For Q4 2025, Current Assets fell 17.42% year-over-year to $2.5 billion; the TTM value through Dec 2025 reached $2.5 billion, down 17.42%, while the annual FY2025 figure was $2.5 billion, 17.42% down from the prior year.
  • Current Assets for Q4 2025 was $2.5 billion at Sarepta Therapeutics, down from $2.7 billion in the prior quarter.
  • Over five years, Current Assets peaked at $3.1 billion in Q4 2024 and troughed at $2.2 billion in Q3 2021.
  • A 5-year average of $2.5 billion and a median of $2.5 billion in 2022 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: rose 20.16% in 2022 and later fell 17.42% in 2025.
  • Year by year, Current Assets stood at $2.6 billion in 2021, then fell by 1.78% to $2.6 billion in 2022, then rose by 0.84% to $2.6 billion in 2023, then increased by 19.16% to $3.1 billion in 2024, then decreased by 17.42% to $2.5 billion in 2025.
  • Business Quant data shows Current Assets for SRPT at $2.5 billion in Q4 2025, $2.7 billion in Q3 2025, and $2.7 billion in Q2 2025.